Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release [Yahoo! Finance]
Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $13.00 to $11.00. They now have a "market perform" rating on the stock.
Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.